On 14 December, Eli Lilly and Company, a global health care leader developing medicines that make life better for people, announced the start of recruitment for the New IDEAS: Imaging Dementia—Evidence for Amyloid Scanning study.
The New IDEAS study, directed by the Alzheimer's Association, will serve as a follow-up to the IDEAS study, which included more than 18,000 participants. The New IDEAS study is an observational, open-label and longitudinal cohort study assessing the impact of amyloid PET brain scans on patient management and associated health outcomes in a more diverse population presenting cognitive impairment. A major limitation of the IDEAS study was a lack of racial and ethnic diversity. The new study will enrol 7,000 US Medicare beneficiaries with mild cognitive impairment or dementia over 30 months, including at least 50% of African American and Hispanic/Latino participants.
